| Policy 01 |
SWOG Mission Statement (4/2018) |
| Policy 02 |
Constitution/ByLaws (5/2023) |
| Policy 03 |
Guidelines for Full Group Institutional Members in SWOG (10/2018) |
| Policy 04 |
National Community Oncology Research Program Guidelines (10/2018) |
| Policy 05 |
Affiliate Program Membership (4/2012) |
| Policy 06 |
Policy Deleted (no download available) |
| Policy 07 |
Individual Membership Process (10/2022) |
| Policy 08 |
Committee Membership Nominations (10/2022) |
| Policy 09 |
Investigator/Clinical Research Associate/Nurse Contribution Sheets (5/2013) |
| Policy 10 |
Job Description of Disease and Research Committee Chair (10/2018) |
| Policy 11 |
Job Description of a Study Chair (10/2022) |
| Policy 12 |
SWOG Registration and Treatment Policies (9/2020) |
| Policy 13 |
Protocol Guidelines (10/2022) |
| Policy 14 |
Policy Deleted (no download available) |
| Policy 15 |
Applicability of IND Applications and Investigator Brochures/Support From Pharmaceutical Companies (4/2011) |
| Policy 16 |
Policy Deleted (no download available) |
| Policy 17 |
Cost Containment (5/2013) |
| Policy 18 |
Data Evaluation Policy and Procedure (9/2020) |
| Policy 19 |
Quality Assurance Program (9/2020) |
| Policy 20 |
New Agent Studies and Safety Monitoring (5/2015) |
| Policy 21 |
Data and Safety Monitoring (5/2013) |
| Policy 22 |
Ethical and Regulatory Considerations (4/2018) |
| Policy 23 |
Serious Adverse Events (10/2022) |
| Policy 24 |
Procedural Guidelines for All SWOG Publications (10/2022) |
| Policy 25 |
Drug Ordering (4/2022) |
| Policy 26 |
The SWOG Radiation Therapy Quality Assurance Committee (4/2019) |
| Policy 27 |
Bone Marrow and Stem Cell Transplantation Guidelines for Institution Approval (5/2014) |
| Policy 28 |
Policy Deleted (no download available) |
| Policy 29 |
Roster of Institutions, Investigators and Associates Maintenance Policies and Procedures (10/2022) |
| Policy 30 |
Responsibility for Patient Follow-Up (8/2023) |
| Policy 31 |
HIPAA Privacy Rule Policy (4/2022) |
| Policy 32 |
Policy deleted (no download available) |
| Policy 33 |
Institutional Performance Review (10/2017) |
| Policy 34 |
Industrial Interaction (5/2013) |
| Policy 35 |
Financial Conflict of Interest Policy (10/2019) |
| Policy 36 |
Affirmation of Integrity (9/2020) |
| Policy 37 |
Policy deleted (no download available) |
| Policy 38 |
Research Calculations for Clinical Trials (10/2021) |
| Policy 39 |
Acquisition, Maintenance and Use in Research of Tissue and Other Biologic Patient Specimens (5/2014) |
| Policy 40 |
Membership of Non-United States Institutions (5/2023) |
| Policy 41 |
Debarment, Suspension or Other Administrative Actions & Handling of Allegations of Research Misconduct (9/2020) |
| Policy 42 |
Policy on Advertising for Subject Recruitment and Trial Promotion (4/2019) |
| Policy 43 |
Requests for Patient Data from Investigators and Pharmaceutical Companies (10/2019) |
| Policy 44 |
Early Closure of Studies (10/2007) |
| Policy 45 |
Press Releases and Trial Publicity (4/2019) |
| Policy 46 |
Job Description of a Principal Investigator (4/2016) |
| Policy 47 |
Intellectual Property Policy (10/2012) |
| Policy 48 |
Job Description of Translational Medicine Subcommittee Chair (5/2013) |
| Policy 49 |
Member Surveys (4/2022) |
